Kevin Allen D'Amour

This inventor holds 47 USPTO granted patents and 22 published patent applications and 18 EPO patents, primarily in Endocrine Cell Development. Top assignees: Viacyte, Inc., Cythera, Inc., Dana-Farber-Cancer Institute Inc.. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kevin Allen D'Amour. Retrieved from https://idiyas.com/inventor/kevin-allen-d-amour

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 47 (Patent Applications = 22)

% Patents Active = 95.7

EPO Patents = 18 (Patent Applications = 22)

Average Co-Inventor Count = 3.5

ph-index = 19

Forward Citations = 1,778(Granted Patents)

Location History:

San Deigo, CA (US) (2011)
San Diego, CA (US) (2009 - 2024)

Company Filing History:

Dana-Farber-Cancer Institute Inc.

The Brigham and Women's Hospital, Inc.

patents

7. 1 out of 871

University of Georgia Research Foundation Inc

patents

8. 1 out of 1,686

W. L. Gore & Associates, Inc.

patents

where one patent can have more than one assignee

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

Universal Donor Cells

Biocompatible Membrane

Pancreatic Endoderm Cells

Endocrine Precursor Cells

Hormone Production

Definitive Endoderm

Stem Cell Differentiation

Blood Glucose Levels

Hepatocyte Lineage Cells

Cell Delivery Devices

Pancreatic Hormones

Methods of Production

47 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12576142 - UNIVERSAL DONOR CELLS AND RELATED METHODS (2026-03-17),

2. 12310830 - Biocompatible membrane composite (2025-05-27),

3. 12173323 - Methods of using PDX1-positive pancreatic endoderm cells and endocrine precursor cells (2024-12-24),

4. 12144908 - PDX1 pancreatic endoderm cells in cell delivery devices and methods thereof (2024-11-19),

5. 11904001 - Universal donor cells and related methods (2024-02-20),

6. 11896622 - Methods of producing pancreatic hormones (2024-02-13),

7. 11746323 - PDX1 positive foregut endoderm cells and methods of production (2023-09-05),

8. 11667889 - Methods of making human primitive ectoderm cells (2023-06-06),

9. 11623023 - PDX1 pancreatic endoderm cells in cell delivery devices and methods thereof (2023-04-11),

10. 11446335 - Cryopreserved endocrine cells that express chromogranin A (2022-09-20),

11. 11427805 - Methods of producing human foregut endoderm cells expressing PDX1 from human definitive endoderm (2022-08-30),

12. 11254916 - Methods of making and using PDX1-positive pancreatic endoderm cells (2022-02-22),

13. 10550367 - Methods of making human primitive ectoderm cells (2020-02-04),

14. 10517901 - Methods of lowering blood glucose levels in a mammal (2019-12-31),

15. 10465162 - Anterior endoderm cells and methods of production (2019-11-05),

Title: Innovations and Contributions of Kevin Allen D'Amour in Biotechnology

Introduction

Kevin Allen D'Amour, based in San Diego, California, is a prolific inventor with a noteworthy portfolio of 45 patents. His work primarily focuses on advancements in biotechnology, particularly in the realm of pancreatic cells and their applications in medical therapies.

Latest Patents

Among his latest contributions are significant patents that revolve around the use of PDX1-positive pancreatic endoderm cells and endocrine precursor cells. These patents disclose enriched cell cultures and populations of immature and mature pancreatic hormone-expressing cells, along with methods for producing such cultures. Another notable patent involves cell delivery devices designed for the transplantation of pancreatic endoderm cells. This innovation includes a specialized cell encapsulation device featuring a lumen, cell-excluding membrane, and protective layers to ensure the proper delivery of cells into a host.

Career Highlights

Throughout his career, Kevin Allen D'Amour has played a vital role in companies such as Viacyte, Inc. and Cythera, Inc. His efforts in these organizations have significantly impacted the development of new therapeutic methods and advancements in the field of regenerative medicine.

Collaborations

Collaborating with esteemed colleagues such as Emmanuel Edward Baetge and Alan D Agulnick, D'Amour has fostered innovation and growth within the biotech industry. These partnerships have led to groundbreaking research and the successful application of his patented technologies.

Conclusion

Kevin Allen D'Amour's innovative spirit and dedication to biotechnology continue to shape the medical landscape. His extensive number of patents showcases his commitment to research and development, paving the way for future breakthroughs in the treatment of pancreatic diseases.

Profile summary based on public USPTO records.